TTF-1 and napsin a do not differentiate metastatic lung adenocarcinomas from primary esophageal adenocarcinomas: Proposal of a novel staining panel

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 8, 2013, Pages 1094-1098

  Aulakh, Kanwaijit S ^a,b   Chisholm, Cary D ^a,d   Smith, Daniel A ^a,c   Speights, V O ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b ST JOHN MEDICAL CENTER   (United States)

^c Central Texas Pathology Laboratory   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; CADHERIN; CDH2 PROTEIN, HUMAN; CDX2 PROTEIN, HUMAN; CK 34 BETA E12; CK-34 BETA E12; HOMEODOMAIN PROTEIN; IMP3 PROTEIN, HUMAN; KERATIN; LEUKOCYTE ANTIGEN; NAPSA PROTEIN, HUMAN; NUCLEAR PROTEIN; RNA BINDING PROTEIN; THYROID NUCLEAR FACTOR 1; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; ESOPHAGUS TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; METASTASIS; METHODOLOGY; PATHOLOGY; STAINING;

ADENOCARCINOMA; ANTIGENS, CD; ASPARTIC ACID ENDOPEPTIDASES; CADHERINS; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL NEOPLASMS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LUNG NEOPLASMS; NUCLEAR PROTEINS; RNA-BINDING PROTEINS; STAINING AND LABELING; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881068501     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0305-OA     Document Type: Article

References (17)

1. Mizobuchi S, Tachimori Y, Kato H, Watanabe H, Nakanishi Y, Ochiai A. Metastatic esophageal tumors from distant primary lesions: report of three esophagectomies and study of 1835 autopsy cases. Jpn J Clin Oncol. 1997; 27(6)410-414.
2. Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol. 1996;9(4):445-452.
3. Whithaus K, Fukuoka J, Prihoda TJ, Jagirdar J. Evaluation of napsin a, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. Arch Pathol Lab Med. 2012;136(2):155-162.
4. Minoo P, Hamdan H, Bu D, Warburton D, Stepanik P, deLemos R. TTF-1 regulates lung epithelial morphogenesis. Dev Biol. 1995;172(2):694-698.
5. Crisera CA, Connelly PR, Marmureanu AR, et al. TTF-1 and HNF-3β in the developing tracheoesophageal fistula: further evidence for the respiratory origin of the distal esophagus. J Pediatr Surg. 1999;34(9):1322-1326.
6. Crisera CA, Maldonado TS, Kadison AS, Li M, Longaker MT, Gittes GK. Patterning of the "distal esophagus" in esophageal atresia with tracheoesophageal fistula: is thyroid transcription factor 1 a player? J Surg Res. 2000; 92(2):245-249.
7. Spilde TL, Bhatia AM, Miller KA, et al. Thyroid transcription factor-1 expression in the human neonatal tracheoesophageal fistula. J Pediatr Surg. 2002; 37(7):1065-1067.
8. Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012; 136(2):163-171.
9. Odze RD, Goldblum JR. Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas. 2nd ed. Philadelphia, PA: Elsevier; 2009.
10. Robens J, Goldstein L, Gown AM, Schnitt SJ. Thyroid transcription factor-1 expression in breast carcinomas. Am J Surg Pathol. 2010;34(12):1881- 1885.
11. Fernández-Aceñero MJ, Córdova S, Santonja C. Aberrant TTF-1 expression in papillary high-grade urothelial neoplasm: case report and literature review. Rom J Morphol Embryol. 2011;52(1):171-174.
12. Xu B, Thong N, Tan D, Khoury T. Expression of thyroid transcription factor- 1 in colorectal carcinoma. Appl Immunohistochem Mol Morphol. 2010;18(3): 244-249.
13. Mazziotta RM, Borczuk AC, Powell CA, Mansukhani M. CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. Appl Immunohistochem Mol Morphol. 2005;13(1):55-60.
14. Rossi G, Cavazza A. CDX2 expression and lung cancer. Appl Immunohistochem Mol Morphol. 2006;14(2):249-250.
15. Strickland-Marmol LB, Khoor A, Livingston SK, Rojiani A. Utility of tissuespecific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain. Arch Pathology Lab Med. 2007;131(11):1686-1690.
16. Lu D, Vohra P, Chu PG, Woda B, Rock KL, Jiang Z. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. Am J Surg Pathol. 2009;33(4):521-525.
17. Kotb AM, Hierholzer A, Kemler R. Replacement of E-cadherin by Ncadherin in the mammary gland leads to fibrocystic changes and tumor formation. Breast Cancer Res. 2011;13(5):R104. doi:10.1186/bcr30